Akcell Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2018 and headquartered in North Miami, Florida, Akcell Biotech is a private, early-revenue stage company operating in the molecular diagnostics space. Its core business involves the sale of proprietary 'AK™PCR' mutation screen kits for key genetic targets like JAK2, BRAF, BRCA1, and KRAS, used in diagnosing various cancers and genetic conditions. The company also lists genomic services, including CRISPR editing and sequencing, suggesting a broader technology services platform alongside its product portfolio.

OncologyImmunologyHematologyGenetic Disorders

Technology Platform

Proprietary real-time PCR (AK™PCR) assays for mutation screening; Genomic services including DNA/RNA isolation, SNP screening, sequencing, and CRISPR editing in microbes.

Opportunities

The growing global demand for personalized medicine and companion diagnostics in oncology creates a significant market for targeted mutation screening kits.

Expanding its service offerings in CRISPR and sequencing could provide a diversified revenue stream and foster R&D collaborations.

Risk Factors

Intense competition from large, established diagnostics companies and evolving clinical standards towards multi-gene NGS panels threaten the demand for single-gene PCR tests.

Lack of publicly disclosed leadership, funding, and clear regulatory strategy for its products creates uncertainty about scalability and market access.

Competitive Landscape

Akcell operates in the highly competitive molecular diagnostics market, competing against giants like Qiagen, Roche, and Thermo Fisher Scientific, as well as numerous specialty diagnostic firms. Its success depends on offering superior performance, cost-effectiveness, or niche targeting for its specific AK™PCR kits.

More companies in Diagnostics & Precision Medicine →More companies in United States →